ArticleMolecular therapy. Oncology2025

Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial.

Hamenth Kumar Palani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.